Revance Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Revance Therapeutics kazanç ve gelirinin sırasıyla yıllık 72.2% ve 22.4% oranında artması tahmin edilirken, EPS'nin yıllık 72.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

72.2%

Kazanç büyüme oranı

72.6%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.6%
Gelir büyüme oranı	22.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	15 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:RVNC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	460	7	55	26	9
12/31/2025	362	-77	-35	-24	9
12/31/2024	277	-157	-108	-53	9
6/30/2024	251	-304	-209	-201	N/A
3/31/2024	240	-325	-221	-213	N/A
12/31/2023	234	-324	-223	-217	N/A
9/30/2023	207	-394	-210	-204	N/A
6/30/2023	179	-337	-214	-211	N/A
3/31/2023	153	-341	-204	-202	N/A
12/31/2022	133	-356	-197	-194	N/A
9/30/2022	109	-274	-214	-208	N/A
6/30/2022	99	-263	-210	-203	N/A
3/31/2022	90	-274	-216	-208	N/A
12/31/2021	78	-281	-232	-222	N/A
9/30/2021	63	-297	-247	-239	N/A
6/30/2021	47	-303	-250	-242	N/A
3/31/2021	29	-292	-218	-210	N/A
12/31/2020	15	-282	-183	-179	N/A
9/30/2020	4	-249	-152	-150	N/A
6/30/2020	0	-209	-129	-126	N/A
3/31/2020	0	-186	-141	-138	N/A
12/31/2019	0	-159	-109	-106	N/A
9/30/2019	1	-155	-108	-104	N/A
6/30/2019	3	-146	-103	-97	N/A
3/31/2019	4	-143	-112	-105	N/A
12/31/2018	4	-143	-111	-104	N/A
9/30/2018	3	-138	-107	-102	N/A
6/30/2018	1	-136	-101	-98	N/A
3/31/2018	0	-128	N/A	-85	N/A
12/31/2017	0	-121	N/A	-95	N/A
9/30/2017	0	-111	N/A	-80	N/A
6/30/2017	0	-99	N/A	-73	N/A
3/31/2017	0	-97	N/A	-65	N/A
12/31/2016	0	-89	N/A	-60	N/A
9/30/2016	0	-85	N/A	-63	N/A
6/30/2016	0	-86	N/A	-62	N/A
3/31/2016	0	-78	N/A	-58	N/A
12/31/2015	0	-73	N/A	-56	N/A
9/30/2015	0	-66	N/A	-48	N/A
6/30/2015	0	-60	N/A	-47	N/A
3/31/2015	0	-57	N/A	-47	N/A
12/31/2014	0	-63	N/A	-55	N/A
9/30/2014	1	-49	N/A	-60	N/A
6/30/2014	1	-48	N/A	-54	N/A
3/31/2014	1	-38	N/A	-62	N/A
12/31/2013	1	0	N/A	-48	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RVNC önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: RVNC önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: RVNC önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: RVNC şirketinin gelirinin (yıllık 22.4% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RVNC şirketinin gelirinin (yıllık 22.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RVNC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Revance Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Forecast to breakeven in 2026

Price target decreased by 18% to US$16.33

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. (NasdaqGM:RVNC) for approximately $720 million.

Revance Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Revance Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Price target decreased by 18% to US$16.33

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Price target decreased by 18% to US$29.25

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Price target decreased by 7.1% to US$33.67

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Price target decreased by 9.0% to US$36.25

Consensus EPS estimates fall by 13%

Senior VP notifies of intention to sell stock

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

CEO & Director notifies of intention to sell stock

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.4m worth of stock

Forecast to breakeven in 2025

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Principal Accounting Officer notifies of intention to sell stock

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.2m worth of stock

No longer forecast to breakeven

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Revance Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Revance Therapeutics, Inc. Submits Supplemental Biologics License Application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia